Vertical: HealthcareBase Year: 202112 Sections
Market Size (2021)
$499.25M
Projected (2030)
$2.12B
CAGR (2018–2030)
16.5%
Key Players
11+
Nanobodies are tiny, recombinantly produced antigen binding VHH fragments, derived from the alpaca heavy chain IgG antibody (HCAb). The key factors contributing to driving the market growth are the increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development. However, manufacturing challenges and high production costs are a threat to the growth of the market. In contrast, a growing development of new applications of nanobodies is likely to create a market opportunity for global market leaders.
The Nanobody Market market is projected to grow at a CAGR of 16.5% from 2018 to 2030.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansNanobodies, also termed sdAbs, are single-domain heavy chain-only antibodies developed from camelids. Nanobodies have numerous beneficial properties, such as their small size that allow them easier access to tissues, high stability, and a robust empathy to their cognate antigen, all of which make them very good candidates for development into next-generation biopharmaceutical agents.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2021
Historical Period
2018 – 2020
Forecast Period
2022 – 2030
Primary Interviews
150+
Historical data (2018–2021) and forecast period (2021–2030)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansNanobodies are single-domain antibodies derived from mammalian heavy-chain antibodies, with unique properties such as nanosized, robust structure, stable and soluble behavior in aqueous solutions and reversible protein refolding among others. Furthermore, the increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development are further expected to drive the growth of the global nanobody market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their devices and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in August 2020, Beroni Group Limited (Australia) announced a collaboration agreement with Genscript Biotech Corporation (US) for the development of a medical solution utilizing nanobody technology for COVID-19, particularly in leading pseudovirus neutralization test, humanization, and affinity maturation of nanobodies with the impartial of increasing the antibody affinity to target the antigen by five to ten-fold.
The global nanobody market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
The business model developed by manufacturers in the global nanobody market includes manufacturing advanced nanobody drugs. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers of nanobodies are also focusing on investing in R&D activities. This will boost market growth in the upcoming future.
With respect to the current scope of the report, Sanofi (France) is the top player in the global nanobody market due to its strong product offering and high preference for its products by customers. Merck KGaA (Germany) is the second major player, followed by Novartis AG (Switzerland), Taisho Pharmaceutical Holdings Co Ltd (Japan), and Beroni Group (Australia). Other key players contributing to the market growth include BIOCYTOGEN (US), Proteintech Group, Inc. (US), GenScript (US), Sensei Biotherapeutics, Inc (US), ExeVir Bio (Belgium), and Dioscure Therapeutics SE (Germany).
Threat of New Entrants
The threat of new entrants is moderate in the global nanobody market due to the development of the potential market. Any nanobody manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards set by the respective regulatory authorities of the country, such as the United States Food and Drug Administration (FDA), The European Medicines Agency (EMA), The Central Drugs Standard Control Organisation (CDSCO), and others. The growing development of new applications of nanobodies pushes the currently established and other manufacturers to focus more on adopting innovative technologies. There is a stronghold of the big companies in this market, which can make the entry of new players challenging. Thus, the threat of new entrants in the market is moderate.
Bargaining Power of Suppliers
The suppliers in the nanobody market are the developers and manufacturers of nanobodies used for treating chronic diseases and diagnostics. The bargaining power of suppliers is a crucial factor in the nanobody market and determines the industry's strength. Many suppliers are currently present in the market due to the availability of a huge patient pool, high demand for treatment, and increasing government support. The existing key companies capture significant market share and monitor the cost of the drugs. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other drug manufacturing companies. Thus, the overall bargaining power of suppliers in the nanobody market is expected to be moderate during the forecast period.
Threat of Substitutes
The threat of substitutes in the global nanobody market is moderate to high. Nanobodies offer several advantages over traditional biologics, such as their small size and high stability among others, the market may face competition from traditional monoclonal antibodies and gene therapy in current times. However, the unique properties of nanobodies, such as their ability to penetrate tissue and cross the blood-brain barrier, may give them an advantage over these substitutes in certain applications.
Bargaining Power of Buyers
The nanobody market is characterized by the presence of a large number of buyers. The market for nanobodies is identified as having a significant customer base, considering the increasing number of patients suffering from chronic diseases such as autoimmune diseases, blood disorders, and others. However, the buyers tend to use the products that have been provided by the top players, as currently there are very limited numbers of players operating in the nanobody market. Thus, the bargaining power of buyers is expected to be low in the nanobody market during the forecast period.
Intensity of Rivalry
The degree of competition in the global nanobody market is high, owing to the presence of a large number of prominent players. Moderate product differentiation among existing players increases the intensity of rivalry in the market. Nanobody manufacturing companies are developing advanced products for differentiating their brand from competitors. Additionally, many prominent market players are entering into strategic partnerships, co-development activities, and tie-ups with established companies to overcome the competition. Thus, the intensity of rivalry in the global nanobody market is expected to be high during the study period.
Market estimates by geography (2030)
InsightNorth America leads with $951.87M by 2030, while Asia Pacific is projected to grow fastest at a 18.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2018 | 2021 | 2030 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $133.48M | $318.47M | $951.87M | 17.8% | 45% |
| Europe | $115.76M | $222.75M | $528.76M | 13.5% | 25% |
| Asia Pacific | $55.72M | $141.47M | $446.00M | 18.9% | 21% |
| Rest of the World | $33.95M | $72.51M | $189.10M | 15.4% | 9% |
| Total | $338.91M | $755.20M | $2.12B | 16.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$2.12B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Mono-Specific | $1.46B | 15.8% | 69% |
| Multi-Specific | $652.04M | 18.2% | 31% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Nanobody Market covering market dynamics, competitive landscape, and strategic outlook.
The Nanobody Market market is projected to reach $2.12B by 2030, growing at 16.5% CAGR. The Mono-Specific segment holds the largest share.
The global nanobody market is emerging due to the increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development. Additionally, the growing development of new applications of nanobodies will provide growth opportunities for the market in the future. However, the manufacturing challenges and high production costs might hamper the market's growth in the forecast period.
There has been a significant increase in the prevalence of chronic diseases such as cancer, autoimmune diseases, neurological disorders, blood disorders, and others which has led to an increased demand for targeted therapies. Nanobodies have shown promise in treating these conditions due to their ability to target specific cells and tissues. Nanobodies are small antibody fragments that have several advantages over traditional antibodies, such as greater stability, better tissue penetration, and reduced immunogenicity. The rising prevalence of autoimmune diseases and other chronic disorders demands the discovery of newer and more effective nanobody-based drugs for their treatment. For instance, in February 2019, the United States Food and Drug Administration (FDA) approved Cablivi (caplacizumab-yhdp), the first nanobody-based medicine of Sanofi S.A. (France), for adults with acquired thrombotic thrombocytopenic purpura (aTTP). The growing incidence of autoimmune diseases such as rheumatoid arthritis and other chronic diseases is anticipated to fuel the market growth during the assessment period. For instance, as per the National Stem Cell Foundation (US), approximately 4% of the world's population is affected by one of more than 80 different autoimmune diseases, the most prevalent of which are type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. Similarly, according to the International Agency for Research on Cancer (France), approximately 19.3 million new cancer cases worldwide in 2020, with lung, breast, colorectal, prostate, and stomach cancers being the most common.
Additionally, according to the World Health Organization (WHO), chronic diseases such as cancer, cardiovascular disease, and diabetes are responsible for 74% of all deaths globally. The incidence and prevalence of these diseases are expected to continue to rise, driven by factors such as aging populations, changing lifestyles, and increasing urbanization. In response to this growing burden, there is a need for new and innovative therapies that can address these diseases effectively. Nanobodies are a promising avenue for drug development in this regard, as they offer several advantages over traditional antibodies. Nanobodies have the ability to target specific disease-causing molecules, such as tumor markers or inflammatory cytokines. This specificity makes them attractive as potential therapeutic agents for a range of chronic diseases. For example, nanobodies have shown promise in preclinical and clinical trials for the treatment of cancer, rheumatoid arthritis, and multiple sclerosis. For instance, M 6495 of Ablynx (Belgium) and Merck KGaA (Germany) initaited phase I trials for osteoarthritis in Denmark. Hence, the increasing prevalence of chronic diseases, combined with the unique advantages of nanobodies drives market growth.
The increase in the development of new applications of nanobodies represents a significant opportunity for the pharmaceutical & biotechnology industry. Nanobodies are a unique class of antibodies that offer a number of advantages over traditional monoclonal antibodies, including their small size, stability, and ability to target difficult-to-reach epitopes. As a result, they are being increasingly explored for a wide range of applications beyond their initial use in research and diagnostics. One of the most promising new applications of nanobodies is in the field of therapeutics. Nanobodies have already shown great potential in treating a variety of diseases, including cancer, infectious diseases, and inflammatory disorders. Additionally, they have been used to develop new imaging agents and diagnostic tools, as well as for targeted drug delivery. Moreover, another area where nanobodies are being explored is the development of new biologics, due to their small size and unique binding properties suited for the development of new therapeutics with improved efficiency and safety. For instance, in November 2022, MassBiologics (US) developed the VHH-IgA biologic, which is a fusion of an antigen-binding fragment of the COVID spike protein and a human IgA antibody for treating SARS-CoV-2 infection. As a result, the nanobody market is expected to see significant expansion due to the growing development of new applications of nanobodies for the diagnosis and treatment of several chronic diseases.
The manufacturing process for nanobodies can be complex and challenging, which is a significant restraint on the development of these therapies. One of the primary challenges is the need for a larger and more complicated infrastructure for the production of nanobodies. This is because nanobodies are derived from camelids, such as llamas or camels, and are typically produced in specialized cells located in the animal’s bone marrow. To produce nanobodies, researchers first need to immunize the animal with the target antigen. This process triggers the production of specialized immune cells called B-cells, which produce nanobodies against the antigen. Once the B-cells have been isolated from the animal, researchers can extract the nanobodies and clone them to produce a large enough quantity for therapeutic use. However, the process of extracting and cloning nanobodies can be complex and time-consuming. In addition, the specialized cells used to produce nanobodies are typically housed in a larger and more complicated system than those used for traditional cell lines, which can add to the manufacturing costs and logistical challenges. Moreover, another challenge associated with the manufacturing process for nanobodies is the need for specific purification methods this requires specialized purification techniques, which can add to the overall cost and complexity of the manufacturing process. Thus, the complex manufacturing process and high production costs for nanobodies are anticipated to restrain the growth of the market.
The pandemic has affected the economic environment for several businesses around the world. The supply chain in the global nanobody market is the key to fulfilling customer demands. As a result of the pandemic, several countries-imposed import and export restrictions. This has also affected the healthcare industry as many countries are dependent on other countries for raw material supply and technology. Raw materials required for manufacturing nanobodies such as antibody-producing cells, growth media, chromatography resins, buffer solutions, and others saw a shortage that hampered the market. Restrictions on international travel and shipping have caused delays in the transportation of raw materials and finished products, leading to supply chain disruptions and shortages. In addition, the pandemic has also led to increased demand for nanobodies that can be used in COVID-19 research and treatment. This has led to shortages of certain types of nanobodies, as manufacturers struggle to keep up with demand. Overall, the COVID-19 pandemic has had a significant impact on the global supply chain of the nanobody market in 2020, leading to delays in manufacturing, shortages of raw materials, and disruptions in shipping and logistics. However, in 2021, as the trade restrictions are lifted as COVID-19 cases decrease, vaccines are made available in different parts of the world, and it has helped the market to recover.
The COVID-19 pandemic has had a significant impact on clinical trials of nanobodies, as it has on many areas of clinical research. The pandemic has led to disruptions in clinical trial enrollment, trial site closures, and delays in data analysis and reporting. One major impact of the pandemic on nanobody clinical trials has been the difficulty in recruiting and retaining study participants, particularly for trials focused on non-COVID-19 indications. Restrictions on travel, social distancing measures, and concerns about exposure to the virus have made it more difficult to recruit and retain participants, particularly those in vulnerable populations or in areas with high rates of COVID-19 transmission.
Furthermore, the pandemic has also caused delays in data analysis and reporting, as trial sponsors and regulatory authorities had to prioritize COVID-19-related research and activities. This has led to longer wait times for trial results and regulatory approvals for nanobody drugs. Overall, the COVID-19 pandemic has had a significant impact on the clinical trials of nanobodies, leading to delays in study start-up, recruitment and retention of participants, and data analysis and reporting. However, researchers and sponsors are working to adapt to these challenges, such as implementing virtual trial visits and telemedicine, to minimize the impact of the pandemic on clinical research.
The pandemic has led to increased demand for nanobodies that can be used in COVID-19 research and treatment. The increased demand for COVID-19-related nanobodies has created opportunities for nanobody manufacturers and suppliers. For example, some nanobody-based diagnostic tests and therapeutics have been developed specifically for COVID-19, and the demand for these products has increased significantly during the pandemic. In addition, some nanobody-based drugs have shown promise in the treatment of COVID-19, leading to increased interest and investment in the development of these products. For instance, in 2020, VHH-72-Fc is a nanobody developed by the VIB-UGent Center for Medical Biotechnology (Belgium). It has been shown to neutralize the SARS-CoV-2 virus and prevent it from infecting human cells in laboratory studies. VHH-72-Fc is currently in preclinical development. Hence, the growing development of COVID-19-related nanobodies is expected to recover and continue to grow in the coming years.
Profiles of 104 companies operating in the Nanobody Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Sydney, Australia Founded: 2014 Workforce: ~57 Company Working: Beroni Group is a global biopharmaceutical company that is involved in the development of innovative drugs and therapies for the treatment of various diseases such as cancer and infectious disease. The company’s diverse product portfolio includes virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products, and a development pipeline targeting cancer and cell therapies. Beroni is majorly involved in developing and commercializing innovative immune cell therapies as well as new drugs to capture the unmet medical needs of cancer patients in China and worldwide. The company has operations in Australia, US, China, and Japan.
Company Headquarters: New Jersey, US Founded: 2002 Workforce: ~5,573 Company Working:GenScript is a biotechnology company that provides solutions for life science applications and research. The company offers services in peptide synthesis, genome editing, cell engineering, mutation and library solutions, preclinical drug development, biologics, and manufacturing. The use of GenScript products is advantageous in the life sciences, vaccine research, immunotherapy, COVID-19 treatment, and new drug development. The company also uses its distinct gene synthesis technique in a number of different industries, such as cell therapies, commercial synthetic materials, translational biomedical development, and life science research. It operates in China, Singapore, Japan, the Netherlands, the UK, and the US.
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Company Headquarters: Bonn, Germany Founded: 2020 Workforce: ~10 Company Working: Dioscure Therapeutics SE is the fastest growing next-generation immunotherapies company which is involved in the development of SARS-CoV-2. The company developed bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergetic amalgamations of single-domain antibodies for the treatment of various infected diseases. The company designed lead candidates which target two separate epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated, and manufactured at a large-scale standardized process. The company has a strong business presence in the Europe region.
Company Headquarters: Ghent, Belgium Founded: 2020 Workforce: ~10 Company Working: ExeVir Bio is a clinical-stage company that is developing novel antibody therapies that are used in the treatment of infectious diseases. The company is utilizing highly innovative and clinically supported VHH technology to develop a treatment for viral infections. ExeVir cooperates closely with Belgium’s leading life sciences research institute VIB, developing new VHH antibodies together with the laboratories. The company has a strong distribution network in the Asia-Pacific region.
Company Headquarters: Massachusetts, US Founded: 2009 Workforce: ~1,300 Company Working: BIOCYTOGEN is a biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. It offers immunoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. It also provides drug development, therapeutic antibody discovery and development, and other services. The company serves over 2,200 clients all over the world. It operates in Haimen Jiangsu, Shanghai, Boston, USA, and Heidelberg, Germany.
18 interactive charts drawn from the Nanobody Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Nanobody By End User Others Parent
Nanobody By End User
Nanobody By Application
Nanobody By TYPE
Nanobody Middle-East, Africa and Latin-America Of Rest Of The World
Nanobody Japan, China, India, South Korea, Australia and Rest Of Asia Pacific By Country
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
